The city of Houston and METRO announced a pilot program that's getting passengers online. Photo via ridemetro.org

METRO is test driving a new feature for its passengers. Select vehicles on a few routes will come with free Wi-Fi on board.

The transportation organization selected the 54 Scott and 204 Spring Park & Ride bus routes and the Green and Purple METRORail lines for the pilot program — in part because of their vicinity to universities and schools, according to a news release from METRO.

"I'm excited we can bring this service to some of our riders. Be it for work, entertainment or personal business, Wi-Fi allows them to stay connected while in transit and improves the overall customer experience," says METRO Board Chair Carrin Patman in the release.

The pilot program, which will run through mid-January, is being funded by $110,220 from the Microsoft Digital Alliance that includes installation and service for over 40 routers. The public-private partnership is also supported by Synnex Corporation, Sierra Wireless, Tracking for Less and AT&T.

"Bringing connectivity to Houston METRO riders is a step forward in the smart city journey, and Microsoft is proud to partner with the city to bring the pilot program to life," says Cameron Carr, director of internet of things strategy, scale and smart city, from Microsoft Corp, in the release.

The announcement is another piece of Mayor Sylvester Turner's Smart City initiative to bring innovation across the city.

"When we first sat down with Microsoft and METRO as part of the Smart City discussions, the first thing we discussed was how can we make the Smart City initiatives inclusive for all residents," says Mayor Turner in the release. "That is why connectivity for everyone, and more efficient public transit was our priority."

Photo via rideMETRO.org

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”